Denmark-based ExpreS2ion Biotechnology and Abivax, a French biotechnology company, have entered into a service and commercial licensing agreement under which the companies will collaborate in their development of a treatment for Ebola.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Expres2ion, Abivax, collaboration, licensing agreement, Ebola